683 related articles for article (PubMed ID: 33682697)
1. CircRNA_100565 contributes to cisplatin resistance of NSCLC cells by regulating proliferation, apoptosis and autophagy via miR-337-3p/ADAM28 axis.
Zhong Y; Lin H; Li Q; Liu C; Shen J
Cancer Biomark; 2021; 30(2):261-273. PubMed ID: 33682697
[TBL] [Abstract][Full Text] [Related]
2. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
[TBL] [Abstract][Full Text] [Related]
3. A novel circular RNA hsa_circRNA_103809/miR-377-3p/GOT1 pathway regulates cisplatin-resistance in non-small cell lung cancer (NSCLC).
Zhu X; Han J; Lan H; Lin Q; Wang Y; Sun X
BMC Cancer; 2020 Dec; 20(1):1190. PubMed ID: 33276753
[TBL] [Abstract][Full Text] [Related]
4. Circ_0020123 enhances the cisplatin resistance in non-small cell lung cancer cells partly by sponging miR-140-3p to regulate homeobox B5 (HOXB5).
Wei D; Zeng J; Rong F; Xu Y; Wei R; Zou C
Bioengineered; 2022 Mar; 13(3):5126-5140. PubMed ID: 35170372
[TBL] [Abstract][Full Text] [Related]
5. The malignant property of circHIPK2 for angiogenesis and chemoresistance in non-small cell lung cancer.
Ren M; Song X; Niu J; Tang G; Sun Z; Li Y; Kong F
Exp Cell Res; 2022 Oct; 419(2):113276. PubMed ID: 35863454
[TBL] [Abstract][Full Text] [Related]
6. Identification of circ_0058357 as a regulator in non-small cell lung cancer cells resistant to cisplatin by miR-361-3p/ABCC1 axis.
Chu D; Li P; Li Y; Shi J; Huang S; Jiao P
Thorac Cancer; 2021 Nov; 12(21):2894-2906. PubMed ID: 34523261
[TBL] [Abstract][Full Text] [Related]
7. Circular RNA PRMT5 knockdown enhances cisplatin sensitivity and immune response in non-small cell lung cancer by regulating miR-138-5p/MYH9 axis.
Xu Y; Zhao R; Wang H; Jiang J; Wang Z; Wang J; Zhang W; Li M
J BUON; 2021; 26(5):1850-1861. PubMed ID: 34761592
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
9. ELF1 suppresses autophagy to reduce cisplatin resistance via the miR-152-3p/NCAM1/ERK axis in lung cancer cells.
Zhao L; Wu X; Zhang Z; Fang L; Yang B; Li Y
Cancer Sci; 2023 Jun; 114(6):2650-2663. PubMed ID: 36846943
[TBL] [Abstract][Full Text] [Related]
10. LncRNA NEAT1 induces autophagy through the miR-128-3p/ADAM28 axis to suppress apoptosis of nonsmall-cell lung cancer.
Xie Y; Zheng ZW; He HT; Chang ZB
Kaohsiung J Med Sci; 2022 Oct; 38(10):933-949. PubMed ID: 36054559
[TBL] [Abstract][Full Text] [Related]
11. Hsa_circ_0007142 contributes to cisplatin resistance in esophageal squamous cell carcinoma via miR-494-3p/LASP1 axis.
Chang N; Ge N; Zhao Y; Yang L; Qin W; Cui Y
J Clin Lab Anal; 2022 May; 36(5):e24304. PubMed ID: 35312115
[TBL] [Abstract][Full Text] [Related]
12. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
[TBL] [Abstract][Full Text] [Related]
13. Circular RNA circ-RNF121 contributes to cisplatin (DDP) resistance of non-small-cell lung cancer cells by regulating the miR-646/SOX4 axis.
Liu Y; Zhai R; Hu S; Liu J
Anticancer Drugs; 2022 Jan; 33(1):e186-e197. PubMed ID: 34387608
[TBL] [Abstract][Full Text] [Related]
14. Exosomal circ_PIP5K1A regulates the progression of non-small cell lung cancer and cisplatin sensitivity by miR-101/ABCC1 axis.
Shao N; Song L; Sun X
Mol Cell Biochem; 2021 Jun; 476(6):2253-2267. PubMed ID: 33570734
[TBL] [Abstract][Full Text] [Related]
15. Exosome-transmitted circVMP1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting miR-524-5p-METTL3/SOX2 axis.
Xie H; Yao J; Wang Y; Ni B
Drug Deliv; 2022 Dec; 29(1):1257-1271. PubMed ID: 35467477
[TBL] [Abstract][Full Text] [Related]
16. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
[TBL] [Abstract][Full Text] [Related]
17. Circular RNA PRMT5 confers cisplatin-resistance via miR-4458/REV3L axis in non-small-cell lung cancer.
Pang J; Ye L; Zhao D; Zhao D; Chen Q
Cell Biol Int; 2020 Dec; 44(12):2416-2426. PubMed ID: 32808744
[TBL] [Abstract][Full Text] [Related]
18. CircRNA B cell linker regulates cisplatin sensitivity in nonsmall cell lung cancer via microRNA-25-3p/BarH‑like homeobox 2 axis.
Liu Y; Hu Y; Zhao C; Lu Q
Anticancer Drugs; 2023 Jun; 34(5):640-651. PubMed ID: 36602424
[TBL] [Abstract][Full Text] [Related]
19. Circular RNAcirc_0076305 Promotes Cisplatin (DDP) Resistance of Non-Small Cell Lung Cancer Cells by Regulating
Wang X; Wang H; Jiang H; Qiao L; Guo C
Cancer Biother Radiopharm; 2023 Jun; 38(5):293-304. PubMed ID: 34339285
[No Abstract] [Full Text] [Related]
20. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
Wang L; Shang X; Feng Q
Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
